During the last two years, four new drugs have been marketed in Spain for the treatment of Relapsing Remitting Multiple Sclerosis. The European Medicines Agency recommended marketing authorization for Teriflunomide (Aubagio®, Genzyme, S.L.U.), Alemtuzumab (Lemtrada®, Genzyme, S.L.U.), Dimethyl Fumarate (Tecfidera®, Biogen Spain, S.L.) and Peginterferon β $\upbeta $-1a (Plegridy®, Biogen Spain, S.L.) based on the efficacy and safety profile showed in clinical trials. More recently, 2 other drugs, Cladribine (Mavenclad®, Merck S.L.U.) y Ocrelizumab (Ocrevus®, Hoffmann-La Roche) have been approved for the treatment of Multiple Sclerosis by the EMA. This review tries to gather the pharmacoeconomic data published to date on these four products, data that can endorse the election of the above mentioned drugs not only from a purely clinical point of view, main aspect for their use, but also from an efficiency approach. In the current unfavorable economic environment, with economic-driven decisions regarding the use of health technologies, using pharmacoeconomic data to support our therapeutic decisions may be useful to provide access to the most adequate therapeutic option to our patients.